The company made this announcement after trading hours on Monday, 9 November 2009.
Meanwhile, the BSE Sensex was up 125.80 points, or 0.76%, to 16,624.52.
On BSE, 870 shares were traded in the counter as against an average daily volume of 24,270 shares in the past one quarter.
The stock hit a high of Rs 263 and a low of Rs 257 so far during the day. The stock had hit a 52-week high of Rs 283.05 on 22 October 2009 and a 52-week low of Rs 132.15 on 6 March 2009.
The small-cap stock had underperformed the market over the past one month till 9 November 2009, falling 0.98% as compared to the Sensex's 0.86% fall. It had outperformed the market in the past one quarter, rising 14.61% as compared to the Sensex's return of 8.83%.
The company's equity capital is Rs 18.02 crore. Face value per share is Rs 5.
The current price of Rs 262 discounts the company's Q2 September 2009 annualized EPS of Rs 37.68, by a PE multiple of 6.95.
The company's formulation facilities in Goa and Ghaziabad are already approved by US Food and Drug Administration, Unichem Laboratories said in a statement to the BSE.
Unichem Laboratories had in August 2009 received approval from US FDA for Clonidine Hydrochloride tablets in multiple strengths. The drug is used for treating hypertension. The drug is the generic version of Boehringer Ingelheim's Catapres tablets.
Unichem Laboratories' net profit declined 3.1% to Rs 33.97 crore on 0.8% fall in net sales to Rs 173.28 crore in Q2 September 2009 over Q2 September 2008.
Unichem Laboratories is engaged in manufacturing and marketing pharmaceutical formulations, bulk drugs and drug intermediates.